Clinical Study
Prognostic Factors for Tumor Recurrence after a 12-Year, Single-Center Experience of Liver Transplantations in Patients with Hepatocellular Carcinoma
Table 4
Analysis of factors affecting one-year tumor recurrence rate in patients with HCC.
| Variables | | One-yr recurrence | P value |
| Gender | Female () | 10 (24) | .3 | Male () | 43 (18) |
| Age | 60 years () | 34 (18) | .8 | 60 years () | 19 (19) |
| AFP 30 ng/mL at OLT | No () | 30 (15) | .01 | Yes () | 22 (28) |
| Viral infection | HCV-positive () | 30 (20) | .8 | HBV-positive () | 13 (19) | HCV, HBV-positive () | 3 (23) | HCV, HBV-negative () | 7 (15) |
| Down-staging to MC | No () | 46 (19) | .8 | Yes () | 7 (18) |
| Preoperative MC | Fulfilled () | 44 (20) | .4 | Not fulfilled () | 9 (15) |
| Preoperative up-to-seven | Fulfilled () | 51 (19) | .7 | Not fulfilled () | 2 (12) |
| Pre-OLT treatments | No () | 4 (7) | .02 | Yes () | 47 (21) |
| Histological MC | Fulfilled () | 36 (17) | .3 | Not fulfilled () | 17 (23) |
| Histological up-to-seven | Fulfilled () | 45 (18) | .4 | Not fulfilled () | 8 (23) |
| Grading | G0–G2 () | 23 (16) | .2 | G3–G4 () | 30 (21) |
| Microvascular invasion | No () | 25 (15) | .06 | Yes () | 28 (24) |
| Macrovascular invasion | No () | 52 (19) | .4 | Yes () | 1 (33) |
| Post-OLT m-TOR inhibitors | No () | 47 (20) | .3 | Yes () | 6 (14) |
|
|
OLT: orthotopic liver transplantation. HCC: hepatocellular carcinoma. AFP: alpha-fetoprotein. MC: Milan criteria. M-TOR: Mammalian Target Of Rapamycin.
|